Compounded GLP-1 drops or tablets vs injections: do the oral versions work?

Oral GLP-1 tablets (specifically FDA-approved, high-dose versions like the Wegovy pill and orforglipron) do work for weight loss, but compounded sublingual drops or patches do not have proven human efficacy.

FDA-Approved Oral Tablets: Effective, with Modest Difference from Injections

High-dose oral GLP-1 tablets have demonstrated significant weight loss in clinical trials, producing results comparable to injectable versions:

• Wegovy (25 mg oral semaglutide): Participants lost an average of 13.6%–17% of body weight over roughly 71–72 weeks, compared to ~15% for injectable Wegovy [2][10].
• Foundayo (Orforglipron): Participants lost about 12% of body weight over 72 weeks, while injectable counterparts (Eli Lilly) typically show 15–20% loss [2][6].
• Mechanism: These pills work the same way as injections, mimicking a hormone to slow digestion, increase fullness, and suppress appetite [2][5].
• Side Effects: Gastrointestinal issues (nausea, vomiting) occur at rates similar to injections [2][6].

While injections still hold a "modest edge" in clinical data (often 1–3% more weight loss), the difference is small, and pills are a practical choice for those avoiding needles [2][10].

Compounded Sublingual Drops & Patches: No Proven Human Evidence

Currently, there is no published human study demonstrating that sublingual semaglutide drops or weight-loss patches produce meaningful weight loss [1][7]:

• Evidence Gap: The only existing study was conducted on rats, and the researchers explicitly stated it cannot guide human dosing [1].
• Unproven Absorption: Experts caution that oral peptide medications can break down in digestion; compounded formulations may have variable ingredients affecting absorption in the GI tract, making efficacy uncertain [6][7].
• FDA Warning: Sublingual GLP-1s have not been studied in humans, so their safety, absorption, and effectiveness are unknown [7].
• Recommendation: Health experts generally recommend FDA-approved oral GLP-1s (like Rybelsus, the Wegovy pill, or orforglipron) because they are tested in large clinical trials for safety and effectiveness, whereas compounded pills have not been proven effective [6].

Specific Brand Recommendations

If you prefer an oral option, choose FDA-approved medications:

• Wegovy (Oral Semaglutide): The upcoming pill version (likely approved in 2025) has shown weight loss approaching injectables [2][7].
• Orforglipron (Foundayo): An oral GLP-1 from Eli Lilly that showed ~12% weight loss and may outperform standard oral semaglutide [2][6].
• Rybelsus (Oral Semaglutide): FDA-approved for diabetes (not weight loss), but available for those preferring an oral option; early trials showed modest weight loss (~9 lbs) compared to high-dose versions [2][10].

Avoid adverstised compounded sublingual drops or patches until human evidence is provided, as they remain unproven [1][6].